Anzeige
Mehr »
Freitag, 25.07.2025 - Börsentäglich über 12.000 News
Lizenz aktiviert - Kooperation fix: Diese Aktie will jetzt den Milliardenmarkt erobern!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T87A | ISIN: US45408X3089 | Ticker-Symbol: IGS1
Tradegate
24.07.25 | 19:41
0,324 Euro
+0,62 % +0,002
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IGC PHARMA INC Chart 1 Jahr
5-Tage-Chart
IGC PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3100,33024.07.
0,3120,33224.07.

Aktuelle News zur IGC PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiIGC Pharma, Inc.: IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025122- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pharma...
► Artikel lesen
MoIGC Pharma, Inc.: IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards161POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist...
► Artikel lesen
10.07.IGC Pharma, Inc.: IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection331- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC)...
► Artikel lesen
30.06.IGC Pharma: EPS erfüllt Schätzungen - Umsatz schlechter als erwartet14
30.06.Earnings Call Transkript: IGC Pharma Q2 2025 verzeichnet strategisches Wachstum in der Alzheimer-Forschung1
30.06.IGC Pharma GAAP EPS of -$0.09 beats by $0.02, revenue of $1.2M misses by $0.25M1
30.06.IGC Pharma, Inc.: IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation360POTOMAC, MARYLAND / ACCESS Newswire / June 30, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging AI to develop innovative treatments...
► Artikel lesen
27.06.IGC Pharma, Inc. - 10-K, Annual Report2
IGC PHARMA Aktie jetzt für 0€ handeln
27.06.Insights Ahead: IGC Pharma's Quarterly Earnings3
27.06.IGC Pharma, Inc.: IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025241POTOMAC, MARYLAND / ACCESS Newswire / June 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company will host a conference call and webcast on Monday...
► Artikel lesen
23.06.IGC Pharma, Inc.: IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon215POTOMAC, MD / ACCESS Newswire / June 23, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the addition of a new clinical trial site at Tekton Research in Yukon,...
► Artikel lesen
17.06.IGC Pharma, Inc. - 8-K, Current Report1
22.05.IGC Pharma, Inc.: IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market477POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA...
► Artikel lesen
12.05.IGC Pharma, Inc.: IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting266POTOMAC, MD / ACCESS Newswire / May 12, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity...
► Artikel lesen
24.04.IGC Pharma, Inc.: IGC Pharma Welcomes Strategic Investment from Advisors348POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share...
► Artikel lesen
21.04.IGC Pharma, Inc.: IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs330Industry Veterans Bring Deep Strategic Experience to Guide Alzheimer's Clinical Expansion and Commercial Strategy POTOMAC, MARYLAND / ACCESS Newswire / April 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC)...
► Artikel lesen
08.04.IGC Pharma, Inc.: IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program378POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial with...
► Artikel lesen
01.04.IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health293POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitation...
► Artikel lesen
26.03.IGC Pharma, Inc.: IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances391- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company")...
► Artikel lesen
20.03.IGC Pharma, Inc.: IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences292POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the...
► Artikel lesen
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1